Cencora, Inc. (COR)
(Delayed Data from NYSE)
$224.81 USD
+2.25 (1.01%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $224.79 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$224.81 USD
+2.25 (1.01%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $224.79 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Cigna (CI) have performed compared to their sector so far this year.
Cencora (COR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Cencora (COR) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medical Product Stocks' Q4 Earnings Due on Jan 30: SYK & More
by Indrajit Bandyopadhyay
Fourth-quarter results of Medical Product companies are likely to reflect a year-over-year improvement in revenues. Let's see how SYK, COR and ARAY fare this time around.
Cencora (COR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Unlocking Q1 Potential of Cencora (COR): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.26% and 1.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Cencora (COR) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Improving membership levels, strategic acquisitions, expanding government business, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.
Elevance Health (ELV) Enhances Whole Health With Paragon Buyout
by Zacks Equity Research
Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.
5 Broker-Favored Stocks to Keep an Eye on in the Current Year
by Maharathi Basu
We believe that stocks like American Airlines (AAL), Alaska Air Group (ALK), Cencora (COR), Cleveland-Cliffs (CLF) and Avnet (AVT) should be on an investor's watchlist.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Teladoc (TDOC) Stock for Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
Why Cencora (COR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches
by Maharathi Basu
We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.